Microvesicles shed from bortezomib-treated or
lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro

Guo,Hui-Mei; Sun,Li; Yang,Lin; Liu,Xiao-Jun; Nie,Zi-Yuan; Luo,Jian-Min

doi:10.3892/or.2018.6395

Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro

Authors:
- Hui-Mei Guo
- Li Sun
- Lin Yang
- Xiao-Jun Liu
- Zi-Yuan Nie
- Jian-Min Luo
View Affiliations

Affiliations: Department of Hematology, The Second Hospital of Hebei Medical University, Key Laboratory of Hematology, Shijiazhuang, Hebei 050000, P.R. China
Published online on: April 23, 2018 https://doi.org/10.3892/or.2018.6395
Pages: 2873-2880

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiogenesis plays a significant role in the pathogenesis of multiple myeloma (MM). Microvesicles (MVs), a type of extracellular vesicles, are known as important players in cell-to-cell communication. MM-derived MVs have exhibited the activity of promoting angiogenesis. Bortezomib and lenalidomide are important drugs for treating myeloma. Therefore, the aim of the present study was to investigate whether and how MVs secreted from human myeloma cells exposed to bortezomib and lenalidomide affect angiogenesis. RPMI-8226 human myeloma cells and human umbilical vein endothelial cells (HUVECs) were used. MVs were isolated from the drug-treated RPMI-8226 cells. The number of the MVs were analyzed with flow cytometry. The expression of pro-angiogenic factors was analyzed with PCR and ELISA. The angiogenic potential of HUVECs was examined. NF-κB activation was analyzed using PCR, immunofluorescent staining and western blotting assays. We showed that bortezomib treatment induced an increase in the number of MVs shed from myeloma cells, but the number of MVs was not significantly altered by lenalidomide. The expression levels of vascular endothelial growth factor (VEGF), interleukin 6 (IL-6) and basic fibroblast growth factor (bFGF) were reduced in the MVs from the RPMI-8226 cells exposed to bortezomib and lenalidomide. Consequently, these MVs exhibited reduced angiogenic potential, as evaluated by wound healing tests, Boyden chamber assays and tube formation assays. Co-culturing HUVECs with drug-treated MVs inhibited NF-κB activation in the HUVECs and reduced the secretion of pro-angiogenic factors. In conclusion, bortezomib and lenalidomide treatment of cultured myeloma cells can block MV-induced angiogenesis and hence provides another mechanism for anti-angiogenic therapy.

View Figures

View References

1	Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood. 111:2516–2520. 2008. View Article : Google Scholar : PubMed/NCBI
2	Gkotzamanidou M, Christoulas D, Souliotis VL, Papatheodorou A, Dimopoulos MA and Terpos E: Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma. Med Sci Monit. 19:1188–1194. 2013. View Article : Google Scholar : PubMed/NCBI
3	Accardi F, Toscani D, Bolzoni M, Dalla Palma B, Aversa F and Giuliani N: Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: Impact on myeloma-induced alterations of bone remodeling. BioMed Res Int. 2015:1724582015. View Article : Google Scholar : PubMed/NCBI
4	Matthes T, Manfroi B, Zeller A, Dunand-Sauthier I, Bogen B and Huard B: Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow. Leukemia. 29:1882–1890. 2015. View Article : Google Scholar : PubMed/NCBI
5	Dankbar B, Padró T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE and Kienast J: Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 95:2630–2636. 2000.PubMed/NCBI
6	van der Pol E, Böing AN, Harrison P, Sturk A and Nieuwland R: Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev. 64:676–705. 2012. View Article : Google Scholar : PubMed/NCBI
7	Todorova D, Simoncini S, Lacroix R, Sabatier F and Dignat-George F: Extracellular Vesicles in Angiogenesis. Circ Res. 120:1658–1673. 2017. View Article : Google Scholar : PubMed/NCBI
8	EL Andaloussi S, Mäger I, Breakefield XO and Wood MJ: Extracellular vesicles: Biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 12:347–357. 2013. View Article : Google Scholar : PubMed/NCBI
9	Canella A, Harshman SW, Radomska HS, Freitas MA and Pichiorri F: The potential diagnostic power of extracellular vesicle analysis for multiple myeloma. Expert Rev Mol Diagn. 16:277–284. 2016. View Article : Google Scholar : PubMed/NCBI
10	Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, Bruno S, Bussolati B and Camussi G: Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood. 110:2440–2448. 2007. View Article : Google Scholar : PubMed/NCBI
11	Zou X, Gu D, Xing X, Cheng Z, Gong D, Zhang G and Zhu Y: Human mesenchymal stromal cell-derived extracellular vesicles alleviate renal ischemic reperfusion injury and enhance angiogenesis in rats. Am J Transl Res. 8:4289–4299. 2016.PubMed/NCBI
12	Lombardo G, Dentelli P, Togliatto G, Rosso A, Gili M, Gallo S, Deregibus MC, Camussi G and Brizzi MF: Activated Stat5 trafficking via endothelial cell-derived extracellular vesicles controls IL-3 pro-angiogenic paracrine action. Sci Rep. 6:256892016. View Article : Google Scholar : PubMed/NCBI
13	Anderson JD, Johansson HJ, Graham CS, Vesterlund M, Pham MT, Bramlett CS, Montgomery EN, Mellema MS, Bardini RL, Contreras Z, et al: Comprehensive proteomic analysis of mesenchymal stem cell exosomes reveals modulation of angiogenesis via nuclear factor-kappab signaling. Stem Cells. 34:601–613. 2016. View Article : Google Scholar : PubMed/NCBI
14	Liu Y, Zhu XJ, Zeng C, Wu PH, Wang HX, Chen ZC and Li QB: Microvesicles secreted from human multiple myeloma cells promote angiogenesis. Acta Pharmacol Sin. 35:230–238. 2014. View Article : Google Scholar : PubMed/NCBI
15	Li ZW, Chen H, Campbell RA, Bonavida B and Berenson JR: NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol. 15:391–399. 2008. View Article : Google Scholar : PubMed/NCBI
16	Chilov D, Kukk E, Taira S, Jeltsch M, Kaukonen J, Palotie A, Joukov V and Alitalo K: Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem. 272:25176–25183. 1997. View Article : Google Scholar : PubMed/NCBI
17	Cramer M, Nagy I, Murphy BJ, Gassmann M, Hottiger MO, Georgiev O and Schaffner W: NF-kappaB contributes to transcription of placenta growth factor and interacts with metal responsive transcription factor-1 in hypoxic human cells. Biol Chem. 386:865–872. 2005. View Article : Google Scholar : PubMed/NCBI
18	Nencioni A, Grünebach F, Patrone F, Ballestrero A and Brossart P: Proteasome inhibitors: Antitumor effects and beyond. Leukemia. 21:30–36. 2007. View Article : Google Scholar : PubMed/NCBI
19	De Luisi A, Ferrucci A, Coluccia AM, Ria R, Moschetta M, de Luca E, Pieroni L, Maffia M, Urbani A, Di Pietro G, et al: Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res. 17:1935–1946. 2011. View Article : Google Scholar : PubMed/NCBI
20	Singhal S and Mehta J: Lenalidomide in myeloma. Curr Treat Options Oncol. 8:154–163. 2007. View Article : Google Scholar : PubMed/NCBI
21	Fremder E, Munster M, Aharon A, Miller V, Gingis-Velitski S, Voloshin T, Alishekevitz D, Bril R, Scherer SJ, Loven D, et al: Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: A process regulated by osteopontin. Int J Cancer. 135:270–281. 2014. View Article : Google Scholar : PubMed/NCBI
22	Munster M, Fremder E, Miller V, Ben-Tsedek N, Davidi S, Scherer SJ and Shaked Y: Anti-VEGF-A affects the angiogenic properties of tumor-derived microparticles. PLoS One. 9:e959832014. View Article : Google Scholar : PubMed/NCBI
23	Zarfati M, Katz T, Avivi I, Brenner B and Aharon A: PO-45 - The role of microvesicles in multiple myeloma progression. Thromb Res. 140 Suppl 1:S1932016. View Article : Google Scholar : PubMed/NCBI
24	Sun L, Wang HX, Zhu XJ, Wu PH, Chen WQ, Zou P, Li QB and Chen ZC: Serum deprivation elevates the levels of microvesicles with different size distributions and selectively enriched proteins in human myeloma cells in vitro. Acta Pharmacol Sin. 35:381–393. 2014. View Article : Google Scholar : PubMed/NCBI
25	Ma GF, Chen S, Yin L, Gao XD and Yao WB: Exendin-4 ameliorates oxidized-LDL-induced inhibition of macrophage migration in vitro via the NF-κB pathway. Acta Pharmacol Sin. 35:195–202. 2014. View Article : Google Scholar : PubMed/NCBI
26	Ribatti D and Vacca A: The role of microenvironment in tumor angiogenesis. Genes Nutr. 3:29–34. 2008. View Article : Google Scholar : PubMed/NCBI
27	Klein B: Positioning NK-kappaB in multiple myeloma. Blood. 115:3422–3424. 2010. View Article : Google Scholar : PubMed/NCBI
28	Podar K and Anderson KC: Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies. Cell Cycle. 6:538–542. 2007. View Article : Google Scholar : PubMed/NCBI
29	Thompson CA, Purushothaman A, Ramani VC, Vlodavsky I and Sanderson RD: Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem. 288:10093–10099. 2013. View Article : Google Scholar : PubMed/NCBI
30	Mineo M, Garfield SH, Taverna S, Flugy A, De Leo G, Alessandro R and Kohn EC: Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion. Angiogenesis. 15:33–45. 2012. View Article : Google Scholar : PubMed/NCBI
31	Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, et al: BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 123:1542–1555. 2013. View Article : Google Scholar : PubMed/NCBI
32	Brill A, Dashevsky O, Rivo J, Gozal Y and Varon D: Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res. 67:30–38. 2005. View Article : Google Scholar : PubMed/NCBI
33	Zhang B, Wu X, Zhang X, Sun Y, Yan Y, Shi H, Zhu Y, Wu L, Pan Z, Zhu W, et al: Human umbilical cord mesenchymal stem cell exosomes enhance angiogenesis through the Wnt4/β-catenin pathway. Stem Cells Transl Med. 4:513–522. 2015. View Article : Google Scholar : PubMed/NCBI
34	Shabbir A, Cox A, Rodriguez-Menocal L, Salgado M and Van Badiavas E: Mesenchymal stem cell exosomes induce proliferation and migration of normal and chronic wound fibroblasts, and enhance angiogenesis in vitro. Stem Cells Dev. 24:1635–1647. 2015. View Article : Google Scholar : PubMed/NCBI